share_log

EFFECT: Others

EFFECT: Others

EFFECT:其他
美股SEC公告 ·  2024/07/17 06:08

Moomoo AI 已提取核心信息

The United States Securities and Exchange Commission (SEC) has declared ZyVersa Therapeutics, Inc.'s submission effective as of July 16, 2024. The company, known for its focus on developing advanced therapies, had its filing accession number 0001493152-24-027033 and submission type POS AM acknowledged by the SEC. This notice of effectiveness is a significant step for ZyVersa Therapeutics, indicating that the regulatory body has reviewed and accepted the company's submission.
The United States Securities and Exchange Commission (SEC) has declared ZyVersa Therapeutics, Inc.'s submission effective as of July 16, 2024. The company, known for its focus on developing advanced therapies, had its filing accession number 0001493152-24-027033 and submission type POS AM acknowledged by the SEC. This notice of effectiveness is a significant step for ZyVersa Therapeutics, indicating that the regulatory body has reviewed and accepted the company's submission.
美国证券交易委员会(SEC)已经宣布ZyVersa Therapeutics,Inc.的提交于2024年7月16日生效。这家以开发先进治疗为重点的公司,其备案文号为0001493152-24-027033,提交类型为pos Am,已得到SEC确认。这个有效通知是ZyVersa Therapeutics的一个重大步骤,表明监管机构已经审核并接受了公司的提交。
美国证券交易委员会(SEC)已经宣布ZyVersa Therapeutics,Inc.的提交于2024年7月16日生效。这家以开发先进治疗为重点的公司,其备案文号为0001493152-24-027033,提交类型为pos Am,已得到SEC确认。这个有效通知是ZyVersa Therapeutics的一个重大步骤,表明监管机构已经审核并接受了公司的提交。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息